Ro Transforms from 'Zombie Company' to Rapid Growth with GLP-1 Drugs

Ro, previously described as a 'zombie company,' has significantly increased its annualized revenue by more than tenfold after revamping its business model. This transformation was driven by the company's adoption of weight-loss treatments involving GLP-1 drugs, marking a major turnaround in its telehealth operations.

Originally published by nyt